将个性化医学“传送”至现实：血液中的突变检测。
BEAMing up personalized medicine: mutation detection in blood.
机构信息
Department of Pathology and Surgery, Brigham and Women's Hospital; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.
出版信息
Clin Cancer Res. 2012 Jun 15;18(12):3209-11. doi: 10.1158/1078-0432.CCR-12-0871. Epub 2012 May 1.
Abstract
BEAMing is a feasible, accurate, and sensitive method for detection of PIK3CA mutations in circulating tumor DNA in blood. Mutation status of PIK3CA may change between primary tumor and recurrence. The results suggest a new approach for noninvasive determination of current mutation status in patients with metastatic disease.
摘要
BEAMing 是一种在血液循环肿瘤 DNA 中检测 PIK3CA 突变的可行、准确和敏感的方法。PIK3CA 的突变状态可能在原发肿瘤和复发之间发生变化。这些结果表明了一种新的方法，可以在转移性疾病患者中进行非侵入性的当前突变状态的检测。
相似文献
1
BEAMing up personalized medicine: mutation detection in blood.将个性化医学“传送”至现实：血液中的突变检测。
Clin Cancer Res. 2012 Jun 15;18(12):3209-11. doi: 10.1158/1078-0432.CCR-12-0871. Epub 2012 May 1.
2
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.使用外周血检测转移性乳腺癌中的肿瘤 PIK3CA 状态。
Clin Cancer Res. 2012 Jun 15;18(12):3462-9. doi: 10.1158/1078-0432.CCR-11-2696. Epub 2012 Mar 15.
3
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.分析循环DNA和蛋白质生物标志物以预测瑞戈非尼的临床活性并评估转移性结直肠癌患者的预后：CORRECT试验的回顾性探索性分析
Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.
4
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.患者同时患有原发性乳腺癌和肺癌，其血浆中检测到 PIK3CA 突变。
Hum Pathol. 2014 Apr;45(4):880-3. doi: 10.1016/j.humpath.2013.10.016. Epub 2013 Oct 31.
5
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.血清DNA中的PIK3CA突变可预测原发性乳腺癌患者的复发情况。
Breast Cancer Res Treat. 2015 Apr;150(2):299-307. doi: 10.1007/s10549-015-3322-6. Epub 2015 Mar 4.
6
Detection of cancer DNA in plasma of patients with early-stage breast cancer.早期乳腺癌患者血浆中癌症DNA的检测
Clin Cancer Res. 2014 May 15;20(10):2643-2650. doi: 10.1158/1078-0432.CCR-13-2933. Epub 2014 Feb 6.
7
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR, HER2 advanced breast cancer: results from BOLERO-2.游离DNA中PIK3CA突变与依维莫司在激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌中的疗效相关性：BOLERO-2研究结果
Br J Cancer. 2017 Mar 14;116(6):726-730. doi: 10.1038/bjc.2017.25. Epub 2017 Feb 9.
8
Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.使用下一代测序技术检测转移性乳腺癌患者游离血浆DNA中的TP53/PIK3CA突变
Clin Breast Cancer. 2016 Oct;16(5):418-423. doi: 10.1016/j.clbc.2016.05.004. Epub 2016 May 14.
9
Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.游离循环DNA检测PIK3CA突变在乳腺癌诊断中的准确性：诊断试验准确性的Meta分析
PLoS One. 2016 Jun 23;11(6):e0158143. doi: 10.1371/journal.pone.0158143. eCollection 2016.
10
Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations.提高循环肿瘤 DNA 突变体恢复的体细胞突变鉴定性能。
Cancer Res. 2016 Oct 15;76(20):5954-5961. doi: 10.1158/0008-5472.CAN-15-3457. Epub 2016 Aug 17.
引用本文的文献
1
Circulating biomarkers in HPV-associated oropharyngeal cancer: Clinical applications of liquid biopsy in diagnosis, prognosis, and surveillance.人乳头瘤病毒相关口咽癌中的循环生物标志物：液体活检在诊断、预后和监测中的临床应用
J Liq Biopsy. 2025 Jul 25;9:100316. doi: 10.1016/j.jlb.2025.100316. eCollection 2025 Sep.
2
The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology.液体活检在乳腺癌中的影响：重新定义非侵入性精准肿瘤学格局。
J Liq Biopsy. 2025 May 21;8:100299. doi: 10.1016/j.jlb.2025.100299. eCollection 2025 Jun.
3
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.液体活检中循环肿瘤DNA的检测：当前技术及其在黑色素瘤中的潜在应用
Int J Mol Sci. 2025 Jan 20;26(2):861. doi: 10.3390/ijms26020861.
4
Effect of icotinib on advanced lung adenocarcinoma patients with sensitive mutation detected in ctDNA by ddPCR.埃克替尼对通过数字滴度PCR在循环肿瘤DNA中检测到敏感突变的晚期肺腺癌患者的疗效。
Transl Cancer Res. 2019 Dec;8(8):2858-2863. doi: 10.21037/tcr.2019.10.48.
5
Computational challenges in detection of cancer using cell-free DNA methylation.使用游离DNA甲基化检测癌症中的计算挑战。
Comput Struct Biotechnol J. 2021 Dec 7;20:26-39. doi: 10.1016/j.csbj.2021.12.001. eCollection 2022.
6
A DNA methylation-based liquid biopsy for triple-negative breast cancer.一种基于DNA甲基化的三阴性乳腺癌液体活检技术。
NPJ Precis Oncol. 2021 Jun 16;5(1):53. doi: 10.1038/s41698-021-00198-9.
7
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with -Mutant, ER-Positive Metastatic Breast Cancer.卡培他滨联合氟维司群或单药治疗 AKT 激酶抑制剂治疗携带突变的 ER 阳性转移性乳腺癌患者。
Clin Cancer Res. 2020 Aug 1;26(15):3947-3957. doi: 10.1158/1078-0432.CCR-19-3953. Epub 2020 Apr 20.
8
A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation.一种新型热点特异性等温扩增方法，用于检测常见的 PIK3CA p.H1047R 乳腺癌突变。
Sci Rep. 2020 Mar 12;10(1):4553. doi: 10.1038/s41598-020-60852-3.
9
Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.应用个体化数字 PCR 技术对转移性癌症循环 DNA 突变进行治疗监测。
J Mol Diagn. 2020 Feb;22(2):247-261. doi: 10.1016/j.jmoldx.2019.10.008. Epub 2019 Dec 16.
10
Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.探索激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌治疗中磷酸肌醇 3-激酶通路激活的生物标志物。
Oncologist. 2019 Mar;24(3):305-312. doi: 10.1634/theoncologist.2018-0314. Epub 2019 Jan 16.
本文引用的文献
1
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.使用外周血检测转移性乳腺癌中的肿瘤 PIK3CA 状态。
Clin Cancer Res. 2012 Jun 15;18(12):3462-9. doi: 10.1158/1078-0432.CCR-11-2696. Epub 2012 Mar 15.
2
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.多区域测序揭示的肿瘤内异质性和分支进化。
N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205.
3
Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.用于I期临床试验患者选择的肿瘤基因检测：以PI3K抑制剂为例
J Clin Oncol. 2012 Mar 10;30(8):765-6. doi: 10.1200/JCO.2011.39.6390. Epub 2012 Jan 23.
4
Clinical trials in the era of personalized oncology.个体化肿瘤学时代的临床试验。
CA Cancer J Clin. 2011 Nov-Dec;61(6):365-81. doi: 10.3322/caac.20135. Epub 2011 Oct 27.
5
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.一种用于快速检测非小细胞肺癌中与靶向治疗相关的多种致癌突变的平台。
J Mol Diagn. 2011 Jan;13(1):74-84. doi: 10.1016/j.jmoldx.2010.11.010. Epub 2010 Dec 23.
6
Genome remodelling in a basal-like breast cancer metastasis and xenograft.基底样乳腺癌转移和异种移植中的基因组重塑。
Nature. 2010 Apr 15;464(7291):999-1005. doi: 10.1038/nature08989.
7
Profiling critical cancer gene mutations in clinical tumor samples.分析临床肿瘤样本中的关键癌症基因突变。
PLoS One. 2009 Nov 18;4(11):e7887. doi: 10.1371/journal.pone.0007887.
8
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.依维莫司联合来曲唑与安慰剂联合来曲唑作为新辅助治疗雌激素受体阳性乳腺癌患者的II期随机研究。
J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.
9
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.乳腺癌中PIK3CA、PTEN和AKT突变的综合基因组和蛋白质组分析。
Cancer Res. 2008 Aug 1;68(15):6084-91. doi: 10.1158/0008-5472.CAN-07-6854.
10
Circulating mutant DNA to assess tumor dynamics.循环突变DNA用于评估肿瘤动态变化。
Nat Med. 2008 Sep;14(9):985-90. doi: 10.1038/nm.1789. Epub 2007 Jul 31.
Zotero 插件